(MENAFN- GlobeNewsWire - Nasdaq) The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and North America dominates the market. Key players include Abbott, Roche, Danaher and Siemens Healthineers.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Point of Care Diagnostics Market by Product, Purchase Mode, Technology, Sample, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.
The global point-of-care diagnostics market is projected to reach USD 31.46 billion by 2031, up from USD 20.63 billion in 2026, representing a compound annual growth rate of 8.8%. Market expansion is being supported by continuous technological advances and rising demand for rapid, accurate and decentralized diagnostic testing across hospitals, clinical laboratories, emergency departments, ambulatory care facilities, physician offices, retail clinics, pharmacies and home healthcare settings.
Biochemistry technology accounts for the largest share of the point-of-care diagnostics market. Its leadership reflects widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing and other routine diagnostic applications. Broad clinical utility, cost-effectiveness and rapid result delivery continue to make biochemistry a preferred technology for high-volume point-of-care testing.
Molecular diagnostics is expected to record the fastest growth during the forecast period. Adoption is increasing for rapid PCR-based platforms used in infectious disease detection, antimicrobial resistance testing and outbreak preparedness. Innovation across immunoassays, molecular platforms, microfluidics, multiplex testing and portable analyzers is improving diagnostic accuracy, shortening turnaround times and extending testing beyond conventional laboratories. Advances in biosensors, artificial intelligence-enabled diagnostics and smartphone-integrated testing solutions are also supporting next-generation point-of-care diagnostic adoption.
Key Market Segment Insights
Product: Infectious disease testing products are projected to register the highest growth during the forecast period. Growth is driven by the increasing burden of infectious diseases, demand for accurate near-patient diagnosis and the need for timely treatment and infection-control decisions. Adoption across hospitals, emergency departments, physician offices, retail clinics, pharmacies and home healthcare settings, combined with government initiatives supporting infectious disease surveillance and decentralized healthcare delivery, is strengthening the segment's market position. End user: Clinical laboratories hold the largest market share due to their central role in rapid diagnostic testing for acute and chronic diseases. These facilities conduct point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring and clinical chemistry. Skilled personnel, extensive testing capabilities, established quality management systems and integration with hospital workflows support continued demand. Higher test volumes, pressure to reduce turnaround times and expanding decentralized testing within laboratory networks further reinforce the segment's leadership.
North America Leads the Global Point-of-Care Diagnostics Market
North America accounts for the largest regional market share, supported by advanced healthcare infrastructure, strong reimbursement frameworks and widespread adoption of decentralized diagnostics. Hospitals, clinical laboratories, physician offices, urgent care centers, retail clinics and pharmacies across the region routinely use point-of-care diagnostics to detect and manage infectious diseases, diabetes, cardiovascular disorders and respiratory conditions.
High healthcare expenditure, favorable regulatory support and the presence of leading diagnostic manufacturers have accelerated adoption in the United States and Canada. The growing focus on early diagnosis, improved patient outcomes and lower healthcare costs through near-patient testing is expected to sustain North America's market leadership.
Competitive Landscape
Prominent companies operating in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMerieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden) and Bio-Rad Laboratories, Inc. (US), among others.
The competitive assessment examines market shares, growth plans, product portfolios, capabilities, company profiles, recent developments and strategic initiatives. It also reviews product launches, anticipated technology trends, investments and market expansion activities shaping competition worldwide.
Research Coverage
The report evaluates the point-of-care diagnostics market and estimates its size and growth potential by product, technology, sample, mode of purchase, end user and region. It provides analysis of established and emerging markets, competitive positioning, product enhancements, innovation pipelines, market diversification and investment activity.
Primary supply-side respondents represented a cross-section of companies, seniority levels and geographic markets:
By company type: Tier 1, 40%; Tier 2, 30%; and Tier 3, 30%. By designation: C-level executives, 55%; director-level respondents, 27%; and others, 18%. By region: North America, 43%; Europe, 28%; Asia Pacific, 20%; Latin America, 6%; and the Middle East and Africa, 3%.
Point-of-Care Diagnostics Market Dynamics
Key drivers: Rising prevalence of diabetes, cardiovascular diseases and infectious diseases; growing demand for decentralized and near-patient testing; greater adoption of portable, user-friendly diagnostic devices in hospitals, clinics and home care settings; and advances in microfluidics, biosensors, AI-enabled diagnostics and smartphone-integrated testing. Market restraints: High costs associated with advanced diagnostic devices and consumables; stringent regulatory approval and quality compliance requirements; accuracy limitations affecting certain rapid tests compared with centralized laboratory testing; and data security and interoperability concerns involving connected diagnostic systems. Growth opportunities: Expansion of point-of-care testing in emerging markets; increasing demand for home-based diagnostic kits and self-testing solutions; wider adoption of multiplex and molecular point-of-care diagnostics; and rising investment in digital health, telemedicine and AI-powered diagnostic platforms. Market challenges: Limited healthcare infrastructure and shortages of trained personnel in low-resource settings; reimbursement and pricing pressures; supply chain constraints affecting reagents and consumables; and the need to standardize and integrate point-of-care diagnostic data with electronic health record systems.
Reasons to Purchase the Report
The report provides market leaders and new entrants with revenue estimates for the overall point-of-care diagnostics market and its subsegments. Stakeholders can use the findings to evaluate market dynamics, identify growth opportunities, understand competitive pressures and develop effective go-to-market strategies. The research also supports product planning, geographic expansion, portfolio diversification and assessment of the growth strategies, offerings and capacities of major competitors.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment